Systemic Lupus Erythematosus Sle clinical trials

Explore recruiting systemic lupus erythematosus sle clinical trials.

Recruiting systemic lupus erythematosus sle studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Lupus Erythematosus Sle trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.

Germany, France, Spain, Poland, Bulgaria, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

France, Denmark, Romania, Czechia, Hungary, Germany +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants with Systemic Lupus Erythematosus (SLE)

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy (OPUS OLE)

France, Portugal, Poland, Germany, Spain, Czechia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus

France, Poland, Italy, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Systemic Lupus Erythematosus Sle trials by city

Systemic Lupus Erythematosus Sle in Toronto Systemic Lupus Erythematosus Sle in Vancouver Systemic Lupus Erythematosus Sle in Montreal Systemic Lupus Erythematosus Sle in Calgary Systemic Lupus Erythematosus Sle in Edmonton Systemic Lupus Erythematosus Sle in Ottawa Systemic Lupus Erythematosus Sle in Winnipeg Systemic Lupus Erythematosus Sle in Quebec City Systemic Lupus Erythematosus Sle in Hamilton Systemic Lupus Erythematosus Sle in Kitchener Systemic Lupus Erythematosus Sle in London Systemic Lupus Erythematosus Sle in Halifax Systemic Lupus Erythematosus Sle in New York Systemic Lupus Erythematosus Sle in Los Angeles Systemic Lupus Erythematosus Sle in Chicago Systemic Lupus Erythematosus Sle in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease